Ultra-Fast List-Mode Reconstruction of Short PET Frames and Example Applications
Conclusion: The presented infrastructure provides the capability to quickly create a series of very short frames for PET data that can be used in a variety of applications. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Spangler-Bickell, M. G., Deller, T. W., Bettinardi, V., Jansen, F. Tags: Clinical Source Type: research

Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury
In this study, we evaluated the role of targeted imaging of very late antigen-4 (VLA-4), as a key integrin mediating the adhesion and recruitment of immune cells to inflamed tissues, in quantifying lung inflammation in a mouse model of lipopolysaccharide-induced ALI. Methods: ALI was induced by a single intratracheal administration of lipopolysaccharide (10, 20, or 40 μg per mouse) in C57BL/6J mice. Control mice were intratracheally instilled with sterile phosphate-buffered saline. VLA-4–targeted PET/CT was performed 24 h after intravenous injection of a 64Cu-labeled high-affinity peptidomimetic ligand referred to...
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Haddad, J., Latoche, J. D., Nigam, S., Bellavia, M. C., Day, K. E., Zhu, Q., Edwards, W. B., Anderson, C. J., Tavakoli, S. Tags: Basic Source Type: research

Dose-Effect Relationships of 166Ho Radioembolization in Colorectal Cancer
Conclusion: A significant dose–response relationship in CRC patients treated with 166Ho radioembolization was established, and a positive association between toxicity and parenchymal dose was found. For future patients, it is advocated to use a 166Ho scout dose to select patients and yo personalize the administered activity, targeting a mean tumor-absorbed dose of more than 90 Gy and a parenchymal dose of less than 55 Gy. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: van Roekel, C., Bastiaannet, R., Smits, M. L. J., Bruijnen, R. C., Braat, A. J. A. T., de Jong, H. W. A. M., Elias, S. G., Lam, M. G. E. H. Tags: Clinical Source Type: research

Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
IgG4-related disease (RD) is characterized by lymphoplasmacytic infiltration enriched in IgG4-positive plasma cells and variable degrees of fibrosis with a characteristic storiform pattern. Since fibrosis is an important feature of IgG4-RD, we performed a prospective cohort study to evaluate the performance of 68Ga-fibroblast activation protein inhibitor (FAPI), a recently introduced PET agent targeting fibroblast activation protein, in IgG4-RD. Methods: Twenty-six patients with IgG4-RD were recruited. All patients underwent both 68Ga-FAPI and 18F-FDG PET/CT. The positive rates of the PET/CT scans in the involved organs an...
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Luo, Y., Pan, Q., Yang, H., Peng, L., Zhang, W., Li, F. Tags: Clinical Source Type: research

Preclinical Development of 18F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-D-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis
Conclusion: 18F-OF-NB1 is a highly promising PET probe for imaging the GluN2B subunits of the N-methyl-d-aspartate receptor. It possesses utility for receptor occupancy studies and has potential for PET imaging studies in ALS patients and possibly other brain disorders. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Ahmed, H., Wallimann, R., Haider, A., Hosseini, V., Gruber, S., Robledo, M., Nguyen, T. A. N., Herde, A. M., Iten, I., Keller, C., Vogel, V., Schibli, R., Wunsch, B., Mu, L., Ametamey, S. M. Tags: Basic Source Type: research

18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging
Conclusion: 18F-SMBT-1 is a promising and selective MAO-B PET tracer candidate, which would be useful for quantitative monitoring of astrogliosis in the human brain. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Harada, R., Hayakawa, Y., Ezura, M., Lerdsirisuk, P., Du, Y., Ishikawa, Y., Iwata, R., Shidahara, M., Ishiki, A., Kikuchi, A., Arai, H., Kudo, Y., Yanai, K., Furumoto, S., Okamura, N. Tags: Basic Source Type: research

Determining Amyloid-{beta} Positivity Using 18F-AZD4694 PET Imaging
Conclusion: Good convergence was obtained among several methods for determining an optimal cutoff for 18F-AZD4694 PET positivity. Despite conceptual and analytic idiosyncrasies linked with dichotomization of continuous variables, an 18F-AZD4694 threshold of 1.55 SUVR had reliable discriminative accuracy. Although clinical use of amyloid PET is currently by visual inspection of scans, quantitative thresholds may be helpful to arbitrate disagreement among raters or in borderline cases. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Therriault, J., Benedet, A. L., Pascoal, T. A., Savard, M., Ashton, N. J., Chamoun, M., Tissot, C., Lussier, F., Kang, M. S., Bezgin, G., Wang, T., Fernandes-Arias, J., Massarweh, G., Vitali, P., Zetterberg, H., Blennow, K., Saha-Chaudhuri, P., Soucy, J.- Tags: Clinical Source Type: research

One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases
Conclusion: SSM/PCA-derived binding patterns of 18F-flortaucipir differentiate between amyloid-positive and -negative neurodegenerative diseases with high accuracy. 18F-flortaucipir PET alone may convey additional information equivalent to that from amyloid PET. Together with a perfusion-weighted early-phase acquisition (18F-FDG PET–equivalent), a single scan potentially contains comprehensive information on amyloid (A), tau (T), and neurodegeneration (N) status as required by recent biomarker classification algorithms (A/T/N). (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Hammes, J., Bischof, G. N., Bohn, K. P., Onur, O., Schneider, A., Fliessbach, K., Honig, M. C., Jessen, F., Neumaier, B., Drzezga, A., van Eimeren, T. Tags: Clinical Source Type: research

Preclinical Characterization of the Radioimmunoconjugate 111In or 90Y-FF-21101 Against a P-Cadherin-Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate
Conclusion: FF-21101 radioimmunotherapy exhibited high antitumor affinity and antitumor efficacy in mouse xenograft models. Extrapolation of the pharmacokinetics in monkeys to humans suggests the potential for clinical application of FF-21101 for treating P-cadherin–expressing tumor. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Funase, Y., Nakamura, E., Kajita, M., Saito, Y., Oshikiri, S., Kitano, M., Tokura, M., Hino, A., Uehara, T. Tags: Basic Source Type: research

Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
Conclusion: PSMA RNT and PD-1 blockade synergistically improve therapeutic outcomes in our PC model, supporting the evaluation of RNT and immunotherapy combinations for PC patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Czernin, J., Current, K., Mona, C. E., Nyiranshuti, L., Hikmat, F., Radu, C. G., Luckerath, K. Tags: Basic Source Type: research

Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors
Conclusion: Our study found that administration of PRRT via the proper hepatic artery did not reproduce the increase in hepatic tumor uptake that was previously reported. In addition, the single treatment using 90Y-DOTATOC did not induce tumor shrinkage, indicating that more treatment cycles may be required. Possible safety concerns in patients with a high liver tumor burden should inform patient selection for future studies. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Lawhn-Heath, C., Fidelman, N., Chee, B., Jivan, S., Armstrong, E., Zhang, L., Lindsay, S., Bergsland, E. K., Hope, T. A. Tags: Clinical Source Type: research

68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer
With the largest high-risk prostate cancer (PCa) cohort to date undergoing 68Ga-prostate-specific membrane antigen (PSMA) PET/CT primary staging, we aimed to, first, characterize the metastatic spread of PCa in relation to tumor 68Ga-PSMA uptake and the D’Amico classification and, second, compare 68Ga-PSMA PET/CT findings with radical prostatectomy and pelvic lymph node dissection (PLND) histopathology findings. Methods: The study included 691 consecutive newly diagnosed, biopsy-proven, treatment-naïve, D’Amico high-risk PCa patients primary-staged by 68Ga-PSMA PET/CT. PSMA SUVmax and metastatic findings w...
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Klingenberg, S., Jochumsen, M. R., Ulhoi, B. P., Fredsoe, J., Sorensen, K. D., Borre, M., Bouchelouche, K. Tags: Clinical Source Type: research

Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
Conclusion: 18F-PSMA-1007 PET/CT reliably detects malignant lymph nodes and has an exceptional specificity of more than 99% for nodal metastases. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Sprute, K., Kramer, V., Koerber, S. A., Meneses, M., Fernandez, R., Soza-Ried, C., Eiber, M., Weber, W. A., Rauscher, I., Rahbar, K., Schaefers, M., Watabe, T., Uemura, M., Naka, S., Nonomura, N., Hatazawa, J., Schwab, C., Schutz, V., Hohenfellner, M., Ho Tags: Clinical Source Type: research

FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Conclusion: The high contrast and low radiation burden of FAPI-74 PET/CT favor multiple clinical applications. Centralized large-scale production of 18F-FAPI-74 or decentralized cold-kit labeling of 68Ga-FAPI-74 allows flexible routine use. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Giesel, F. L., Adeberg, S., Syed, M., Lindner, T., Jimenez-Franco, L. D., Mavriopoulou, E., Staudinger, F., Tonndorf-Martini, E., Regnery, S., Rieken, S., El Shafie, R., Rohrich, M., Flechsig, P., Kluge, A., Altmann, A., Debus, J., Haberkorn, U., Kratochw Tags: Clinical Source Type: research

Predicting Gemcitabine Delivery by 18F-FAC PET in Murine Models of Pancreatic Cancer
Conclusion: 18F-FAC PET was shown to be a good surrogate for gemcitabine uptake and, when combined with MR, to successfully determine drug uptake in tumors growing in the pancreas. PEGPH20 had moderate effects on tumor uptake of gemcitabine. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Russell, J., Grkovski, M., ODonoghue, I. J., Kalidindi, T. M., Pillarsetty, N., Burnazi, E. M., Kulick, A., Bahr, A., Chang, Q., LeKaye, H. C., de Stanchina, E., Yu, K. H., Humm, J. L. Tags: Basic Source Type: research

Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma
Fixed-dose pembrolizumab (200 mg absolute, day 1, every 3 wk) for the treatment of malignant pleural mesothelioma did not result in survival benefit in the phase 3 PROMISE-meso trial compared with second-line chemotherapy. Because of lack of validated imaging response criteria, responder subgroups with potential survival benefit have not yet been identified. Here, we administered high-dose pembrolizumab (10 mg/kg, day 1, every 2 wk) considering the KEYNOTE-028 trial and assessed the prognostic value of PET metabolic response in patients with chemotherapy-resistant malignant mesothelioma of the pleura or peritoneum. Methods...
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Ferdinandus, J., Barbato, F., Chodyla, M., Fendler, W. P., Kessler, L., Pomykala, K. L., Metzenmacher, M., Krefting, F., Hager, T., Umutlu, L., Herrmann, K., Christoph, D. C. Tags: Clinical Source Type: research

18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer
Conclusion: Simultaneous HDACIs and AI dosing in patients with cancer resistant to AI alone showed clinical benefit (6 or more months without progression) in 4 of 10 evaluable patients. Higher 18F-fluoroestradiol PET uptake identified patients likely to benefit from combination therapy, but vorinostat did not change ER expression at the level of detection of 18F-fluoroestradiol PET. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Peterson, L. M., Kurland, B. F., Yan, F., Jiresova, A. N.-, Gadi, V. K., Specht, J. M., Gralow, J. R., Schubert, E. K., Link, J. M., Krohn, K. A., Eary, J. F., Mankoff, D. A., Linden, H. M. Tags: Clinical Source Type: research

Assessment of Bone Lesions with 18F-FDG PET Compared with 99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management
Conclusion: In this exploratory analysis of newly diagnosed MBC patients, 18F-FDG PET versus BS to assess bone lesions resulted in clinically relevant management differences in 16% of patients. BS delivered insufficient information in over one fourth of patients, resulting in an additional request for 18F-FDG PET. On the basis of these data, 18F-FDG PET should be considered a primary imaging modality for assessment of bone lesions in newly diagnosed MBC. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: van Es, S. C., Velleman, T., Elias, S. G., Bensch, F., Brouwers, A. H., Glaudemans, A. W. J. M., Kwee, T. C., Iersel, M. W.-v., Maduro, J. H., Oosting, S. F., de Vries, E. G. E., Schroder, C. P. Tags: Clinical Source Type: research

Quantitative clinical nuclear cardiology, part 2: Evolving/emerging applications
This article discusses evolving methods to measure myocardial blood flow with positron emission tomography and single-photon emission computed tomography. Novel quantitative assessments of myocardial viability, microcalcification and in patients with cardiac sarcoidosis and cardiac amyloidosis will also be described. Lastly, we will review the potential role for artificial intelligence to improve image analysis, disease diagnosis, and risk prediction. The potential clinical role for all these novel techniques will be highlighted as well as methods to optimize their implementation. (J Nucl Cardiol 2020) (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Slomka, P. J., Moody, J. B., Miller, R. J. H., Renaud, J. M., Ficaro, E. P., Garcia, E. V. Tags: Continuing Education Source Type: research

The Latest Developments in Imaging of Fibroblast Activation Protein
Fibroblast activation protein (FAP), a membrane-anchored peptidase, is highly expressed in cancer-associated fibroblasts in more than 90% of epithelial tumors and contributes to progression and worse prognosis of different cancers. Therefore, FAP is considered a promising target for radionuclide-based approaches for diagnosis and treatment of tumors and for the diagnosis of nonmalignant diseases associated with a remodeling of the extracellular matrix. Accordingly, a variety of quinolone-based FAP inhibitors (FAPIs) coupled to chelators were developed displaying specific binding to human and murine FAP with a rapid and alm...
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Altmann, A., Haberkorn, U., Siveke, J. Tags: Focus on Molecular Imaging Source Type: research

11C Dosimetry Scans Should Be Abandoned
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Zanotti-Fregonara, P., Lammertsma, A. A., Innis, R. B. Tags: Hot Topics Source Type: research

Real-World Data as an Evidence Source in Nuclear Medicine
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Bourla, A. B., Herrmann, K. Tags: Editorials Source Type: research

68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership
This article briefly describes the background, clinical development, regulatory approach, and regulatory process for NDA filing and approval. In the second part of this article, key chemistry, manufacturing, and controls (CMC) information is provided to facilitate abbreviated new drug application (ANDA) submission. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Carlucci, G., Ippisch, R., Slavik, R., Mishoe, A., Blecha, J., Zhu, S. Tags: The State of the Art Source Type: research

Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Sartor, O., Hope, T. A., Calais, J., Fendler, W. P. Tags: Discussions with Leaders Source Type: research

The Solutions Come from Science and Knowledge
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Czernin, J., Radu, C. Tags: Editor ' s Page Source Type: research

FDA Announces Priority Review of 18F-DCFPyL NDA
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

SNMMI Leadership Update: Advancing Radiopharmaceutical Therapy
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Wahl, R. L. Tags: SNMMI Newsline Source Type: research

2020 SNMMI Highlights Lecture: Neuroscience
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Price, J. Tags: SNMMI Newsline Source Type: research

FDA Approves First PSMA-Targeted PET Drug
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

SNMMI Newsline
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research

This Month in JNM
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Tags: This Month in JNM Source Type: research

Distribution Volume of 18F-BMS-986192 in NSCLC Patients
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Laffon, E., Marthan, R. Tags: Letters Source Type: research

Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44
Conclusion: We developed a CD44-specific scFv-Fc construct that binds with nanomolar affinity to human CD44. When radiolabeled with 64Cu or 89Zr, it demonstrated specific uptake in CD44-expressing MDA-MB-231 tumors. The high tumor uptake (~56% injected dose/g) warrants clinical investigation of [89Zr]Zr-DFO-scFv-Fc-CD44 as a versatile PET imaging agent for patients with CD44-positive tumors. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Diebolder, P., Mpoy, C., Scott, J., Huynh, T. T., Fields, R., Spitzer, D., Bandara, N., Rogers, B. E. Tags: Basic Source Type: research

Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets
Conclusion: This work demonstrated a robust method for the cyclotron production of scandium radionuclides that could be used with natural or enriched TiO2 target material. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Loveless, C. S., Blanco, J. R., Diehl, G. L., Elbahrawi, R. T., Carzaniga, T. S., Braccini, S., Lapi, S. E. Tags: Radiochemistry Source Type: research

Investigating Low-Dose Image Quality in Whole-Body Pediatric 18F-FDG Scans Using Time-of-Flight PET/MRI
Conclusion: Reductions to the lowest recommended pediatric dosing regimens are possible when using PET/MRI. The data suggest that the administered dose can be decreased to 2.46 MBq/kg, a 33% reduction in PET activity, with no degradation in image quality, leading to a corresponding reduction in absorbed dose. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Schmall, J. P., Surti, S., Otero, H. J., Servaes, S., Karp, J. S., States, L. J. Tags: Physics and Instrumentation Source Type: research

Experience with Esophagogastrointestinal Transit Scintigraphy in the Initial 229 Patients: Multiple Regions of Dysmotility Are Common
Conclusion: This study highlights the frequent occurrence of dysmotility in more than 1 region of the gastrointestinal tract in patients with a suspected motility disorder and the frequent concurrence of both upper- and lower-tract dysmotility in the same patients. It provides information to referring physicians regarding which motility disorders may be causing the patient symptoms, why the patient is or is not responding to the present therapy, and if and what additional workup and therapy may be needed. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Ziessman, H. A., Jeyasingam, M., Khan, A. U., McMahan, Z., Pasricha, P. J. Tags: Clinical Source Type: research

Targeted PET Imaging of Chemokine Receptor 2-Positive Monocytes and Macrophages in the Injured Heart
Conclusion: This work establishes the utility of 64Cu-DOTA-ECL1i to image CCR2+ monocytes and macrophages in mouse models and provides the requisite preclinical information to translate the targeted clinical-grade CCR2 imaging probe for clinical investigation of heart diseases. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Heo, G. S., Bajpai, G., Li, W., Luehmann, H. P., Sultan, D. H., Dun, H., Leuschner, F., Brody, S. L., Gropler, R. J., Kreisel, D., Lavine, K. J., Liu, Y. Tags: Basic Source Type: research

SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0
PREAMBLE The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional nonprofit medical association founded in 1985 to facilitate communication worldwide among individuals pursuing clinical and academic excellence in nuclear medicine. SNMMI and EANM members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine. The SNMMI and EANM will periodic...
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Vali, R., Alessio, A., Balza, R., Borgwardt, L., Bar-Sever, Z., Czachowski, M., Jehanno, N., Kurch, L., Pandit-Taskar, N., Parisi, M., Piccardo, A., Seghers, V., Shulkin, B. L., Zucchetta, P., Lim, R. Tags: Clinical Source Type: research

Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
Conclusion: PBPK modeling and simulations represent an elegant approach to individually determine the minimal tumor perfusion and minimal receptor density required to achieve an adequate TCP. This computational method can be used in the radiopharmaceutical development process for ligand and target selection for specific types of tumors. In addition, this method could be used to optimize clinical trials. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Jimenez-Franco, L. D., Glatting, G., Prasad, V., Weber, W. A., Beer, A. J., Kletting, P. Tags: Basic Source Type: research

PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study
Conclusion: PSMA PET/CT localized prostate cancer lesions in 75% of patients and M1 disease in 45%. Detection of early CRPC facilitates disease-delaying therapies for local or oligometastatic disease. PSMA PET/CT is of value in early CRPC and should be included in the CRPC entry criteria of the European Association of Urology and Prostate Cancer Working Group 3. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Weber, M., Kurek, C., Barbato, F., Eiber, M., Maurer, T., Nader, M., Hadaschik, B., Grunwald, V., Herrmann, K., Wetter, A., Fendler, W. P. Tags: Clinical Source Type: research

The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
This study assessed orally administered monosodium glutamate (MSG) as a potential means of reducing kidney and salivary gland radiation exposure using a PSMA-targeting radiotracer. Methods: This prospective, double-blind, placebo-controlled study enrolled 10 patients with biochemically recurrent prostate cancer. Each subject served as his own control. PET/CT imaging sessions using 2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) were performed 3–7 d apart, after oral administration of either 12.7 g of MSG or placebo. Data from the 2 sets of images were analyz...
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Harsini, S., Saprunoff, H., Alden, T., Mohammadi, B., Wilson, D., Benard, F. Tags: Clinical Source Type: research

64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection
Conclusion: The imaging time window of 64Cu-DOTATATE PET/CT for patients with NENs can be expanded from 1 h to 1–3 h without significant differences in the number of lesions detected. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Loft, M., Carlsen, E. A., Johnbeck, C. B., Johannesen, H. H., Binderup, T., Pfeifer, A., Mortensen, J., Oturai, P., Loft, A., Berthelsen, A. K., Langer, S. W., Knigge, U., Kjaer, A. Tags: Clinical Source Type: research

Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy
Conclusion: Peptide receptor radionuclide therapy can lead to bowel obstruction in patients with mesenteric or peritoneal disease, likely by inducing inflammation. Corticosteroids can potentially play a role in treatment and prophylaxis. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Strosberg, J. R., Al-Toubah, T., Pelle, E., Smith, J., Haider, M., Hutchinson, T., Fleming, J. B., El-Haddad, G. Tags: Clinical Source Type: research

Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients as an Indication for Radioiodine Adjuvant Therapy: A Prospective Multicenter Study
Conclusion: Our study demonstrated that over 90% of TT-DTC patients with unexplained hyperthyroglobulinemia are stratified as being at intermediate to high risk, and RAT using 5.55 GBq of 131I reveals biochemical, functional, or structural disease and yields a non–structurally or –functionally incomplete response in more than 80% patients, suggesting that TT-DTC patients with unexplained hyperthyroglobulinemia are explicit candidates for RAT. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Cheng, L., Sa, R., Luo, Q., Fu, H., Jin, Y., Tang, L., Yang, Y., Yu, C., Chen, L. Tags: Clinical Source Type: research

TAG-72-Targeted {alpha}-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody
Conclusion: These results establish the potential for antibody-targeted α-radionuclide therapy for ovarian cancer, which may be generalized to α-radioimmunotherapy in other solid tumors. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Minnix, M., Li, L., Yazaki, P. J., Miller, A. D., Chea, J., Poku, E., Liu, A., Wong, J. Y. C., Rockne, R. C., Colcher, D., Shively, J. E. Tags: Basic Source Type: research

The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer
Radiolabeled bisphosphonates such as 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) typically show intense uptake in skeletal metastases from metastatic castration-resistant prostate cancer (mCRPC). Extensive bone involvement is regarded as a risk factor for mCRPC patients treated with 223Ra-dichloride (223Ra). The aim of this study was to quantify 99mTc-DPD uptake by means of SPECT/CT before 223Ra and compare the results with the feasibility of treatment and overall survival (OS). Methods: Sixty consecutive mCRPC patients were prospectively included in this study. SPECT/CT of the central skeleton covering ...
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Dittmann, H., Kaltenbach, S., Weissinger, M., Fiz, F., Martus, P., Pritzkow, M., Kupferschlaeger, J., la Fougere, C. Tags: Clinical Source Type: research

124I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma
The metaiodobenzylguanidine (MIBG) scan is one of the most sensitive noninvasive lesion detection modalities for neuroblastoma. Unlike 123I-MIBG, 124I-MIBG allows high-resolution PET. We evaluated 124I-MIBG PET/CT for its diagnostic performance as directly compared with paired 123I-MIBG scans. Methods: Before 131I-MIBG therapy, standard 123I-MIBG imaging (5.2 MBq/kg) was performed on 7 patients, including whole-body (anterior–posterior) planar imaging, focused-field-of-view SPECT/CT, and whole-body 124I-MIBG PET/CT (1.05 MBq/kg). After therapy, 2 of 7 patients also completed 124I-MIBG PET/CT as well as paired 123I-MI...
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Aboian, M. S., Huang, S.-y., Hernandez-Pampaloni, M., Hawkins, R. A., VanBrocklin, H. F., Huh, Y., Vo, K. T., Gustafson, W. C., Matthay, K. K., Seo, Y. Tags: Clinical Source Type: research

Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the {Delta}SUVmax Method
Conclusion: When considering treatment intensification, the currently used Deauville score cutoff of an uptake above that of the liver seems to be inappropriate and associated with potential harm for DLBCL patients. The SUVmax criterion of a relative reduction in SUVmax of less than or equal to 66% should be considered as an alternative. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Rekowski, J., Huttmann, A., Schmitz, C., Muller, S. P., Kurch, L., Kotzerke, J., Franzius, C., Weckesser, M., Bengel, F. M., Freesmeyer, M., Hertel, A., Krohn, T., Holzinger, J., Brink, I., Haberkorn, U., Nyuyki, F., van Assema, D. M. E., Geworski, L., Ha Tags: Clinical Source Type: research

Deep-Learning 18F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma
We examined whether an artificial intelligence–based method could estimate TMTV with a comparable prognostic value to TMTV measured by experts. Methods: Baseline 18F-FDG PET/CT scans of 301 DLBCL patients from the REMARC trial (NCT01122472) were retrospectively analyzed using a prototype software (PET Assisted Reporting System [PARS]). An automated whole-body high-uptake segmentation algorithm identified all 3-dimensional regions of interest (ROIs) with increased tracer uptake. The resulting ROIs were processed using a convolutional neural network trained on an independent cohort and classified as nonsuspicious or su...
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Capobianco, N., Meignan, M., Cottereau, A.-S., Vercellino, L., Sibille, L., Spottiswoode, B., Zuehlsdorff, S., Casasnovas, O., Thieblemont, C., Buvat, I. Tags: Clinical Source Type: research

FDA Guidance on Clinical Trial Diversity
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Tags: SNMMI Newsline Source Type: research